At first glance, the ballot initiative looked like a boon for American biomedical science.
Californians this month voted to pass Proposition 38, a measure authorizing $8.4 billion for immunology research amid cuts and delays to federal grants for science.
But, for some scientists, the boon appears to be more of a boondoggle.
Half of the money, which proponents say will go to potentially lifesaving research on diseases like cancer and Alzheimer’s, appears to be destined for a single institution: the California Institute for Immunology and Immunotherapy, or C.I.I.I.
The institute was co-founded and substantially funded by the billionaire Dr. Gary Michelson, who spent $66 million of his own fortune to bankroll the campaign to pass Proposition 38.
The proposition’s critics say the institute stands to benefit unfairly, given that the state’s other research facilities will have to compete for the remaining half of the money. Now, some are considering challenging the measure in court, arguing that it could violate California’s Constitution.
“A billionaire was able to pay to get this proposition on the ballot and get money he wanted for his research institute,” said Sarah Hill, a professor at California State University, Fullerton. “I don’t think the voters understood what was going on. They thought, ‘We’re going to cure cancer and Alzheimer’s!’ Of course, we all want that. But this is not how public funds are spent.”
Americans tend to think of ballot measures as a purer kind of democracy, less tainted by money in politics, said Lauren Taylor, an assistant professor at New York University. But the campaign in support of Proposition 38 raised around 6,000 times the amount that the opposing side did.
Here is how Proposition 38 works: In an effort to insulate long-term research from statehouse budget fluctuations, California will borrow money from investors through the sale of bonds rather than take it from the state’s coffers. The state will eventually have to repay those loans, with interest — but 10 percent of revenues from therapies that may be developed through these grants will help cover that cost.
Half of the borrowed money will become grants that scientists at various institutions can compete for. The other half will go to a single institution. It isn’t named in the proposition. But it is described with such specificity, down to the square footage, that only one place appears to qualify.
The one facility matching the description, as CalMatters first reported this summer, is C.I.I.I.
Robin Swanson, a spokesperson for the group that backed the measure, acknowledged that the institute will be the likely recipient, though the decision rests with the California Department of Public Health.
Opponents say leaving the institute’s name off the measure was an attempt to slip through a loophole in the California Constitution.
Eve Panush, a lawyer retired from the state’s legislative counsel, who worked to oppose the proposition, said that the law invalidated any initiative that gives a specific private corporation a function or duty, whether or not it is named.
“The constitutional prohibition is against ‘identifying’ the corporation,” she said. “These criteria are such that it would only apply to one corporation in the state. So more or less, the Prop 38 does identify a corporation.”
Ms. Swanson said the proposition’s supporters were confident the measure passed constitutional muster. The California attorney general’s office declined to comment, saying it cannot provide legal advice or analysis.
To the backers of Proposition 38, the plan is a moonshot that creates a research ecosystem, well equipped for large clinical trials.
“The passage of Proposition 38 marks the beginning of a fantastic new era of scientific discovery that will transform how we prevent, treat and cure the world’s most devastating diseases like cancer, Alzheimer’s, Parkinson’s, heart disease, diabetes, hypertension, autoimmune disorders, and so many more,” Dr. Michelson said in an emailed statement.
Most commentators agree that funding biomedical research is a good use of philanthropic funds.
“I bluntly wish more billionaires gave a crap about curing illnesses,” said Jacob Sherkow, a University of Illinois professor of law and medicine. “If we need to adorn them with laurels, then boy, that seems like a good trade off. Laurels are cheap.”
But he and other observers say the math doesn’t add up.
Dr. Sherkow was skeptical that this measure would churn out medications profitable enough to reimburse the state and balked at the ballot measure’s promise to give Californians a 20 percent discount. Those drugs would still have to be prescribed through the Rube Goldberg mechanics of the health care system.
He said that similar ballot measures funded the California Institute for Regenerative Medicine, starting in 2004, in response to President George W. Bush’s restrictions on stem-cell research. In two decades, that center has produced only one approved treatment.
Without adequate revenue from therapies funded by Proposition 38, taxpayers would end up footing the bill.
Dr. Michelson has a good track record of bringing medical breakthroughs to the public. He also has prior experience cooperating on ventures with the state — and with the fickleness of political budgets.
He started out as a spinal surgeon, patenting hundreds of new techniques and winning a $1.35 billion settlement from the medical device giant Medtronic. He and his wife, Alya Michelson, have since put those proceeds toward various causes, including a mobile spay-and-neuter clinic for Los Angeles pets, a biomedical research center at the University of Southern California and an institute promoting education about intellectual property.
C.I.I.I. is affiliated with the University of California, Los Angeles, but it is a nonprofit not subject to the same laws that allow the public to access its records. It had zero employees a few years ago. In September, it had three, but there are plans to ramp up operations.
Dr. Michelson is chair of the institute’s board, and in 2024, he donated $120 million to help set up C.I.I.I. on the site of a former mall. The effort was bolstered by other philanthropists and the state government, which initially pledged $500 million but ended up spending only $200 million.
That $300 million shortfall, Ms. Swanson said, played no role in Proposition 38’s origin story.
The post California Research Measure Is a Windfall for a Billionaire’s Pet Project appeared first on New York Times.




